GlassScriptPhysician profile
Elizabeth C Hawk
NPI 1659327484
$2,186.49
in general payments reported to CMS, 2019-2025
25 companies · $921 in 2025
The $921 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.71 · 2021: $20.17 · 2022: $202 · 2023: $348 · 2024: $650 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $376.08 | 2022-2025 | |
| Novo Nordisk INC | $252.75 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $224.25 | 2019-2025 | |
| Abbott Laboratories | $157.84 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $155.53 | 2024-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $154.53 | 2023-2025 | Veozah |
| Lilly USA, LLC | $123.40 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $120.18 | 2019-2025 | Shingrix, Arexvy |
| Coloplast Corp | $110.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $82.57 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $71.27 | 2024-2025 | Airsupra |
| Medtronic, INC. | $52.52 | 2022-2024 | Interstim |
| Dexcom, INC. | $51.45 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $30.00 | 2025 | |
| Edwards Lifesciences Corporation | $27.11 | 2024 | Sapien 3 Ultra Resilia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $26.47 | 2023 | Contrave |
| Ucb, INC. | $23.34 | 2024 | Nayzilam |
| Inspire Medical Systems, INC. | $23.13 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.72 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $20.66 | 2023 | Dificid |
| Exact Sciences Corporation | $18.45 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.02 | 2025 | Jardiance |
| Becton, Dickinson and Company | $17.08 | 2024 | Venclose Maven Catheter |
| Sumitomo Pharma America, INC. | $14.35 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $14.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.